Randall Stanicky
Stock Analyst at RBC Capital
(2.30)
# 2,512
Out of 4,835 analysts
32
Total ratings
60%
Success rate
5.18%
Average return
Main Sectors:
Stocks Rated by Randall Stanicky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $129 → $135 | $181.68 | -25.69% | 10 | Feb 4, 2021 | |
| PRGO Perrigo Company | Downgrades: Sector Perform | $59 → $49 | $26.29 | +86.38% | 8 | Jan 6, 2021 | |
| PFE Pfizer | Downgrades: Sector Perform | $43 → $42 | $22.60 | +85.84% | 3 | Dec 16, 2020 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $170 → $180 | $106.07 | +69.70% | 2 | Nov 3, 2020 | |
| MRK Merck & Co. | Maintains: Sector Perform | $92 → $89 | $74.80 | +18.98% | 1 | Apr 1, 2020 | |
| AMRX Amneal Pharmaceuticals | Maintains: Sector Perform | $3 → $4 | $7.50 | -46.67% | 3 | Jan 2, 2020 | |
| OPTN OptiNose | Initiates: Outperform | $495 | $9.56 | +5,077.82% | 1 | Nov 7, 2017 | |
| TEVA Teva Pharmaceutical Industries | Downgrades: Underperform | n/a | $16.87 | - | 3 | Aug 4, 2017 | |
| PCRX Pacira BioSciences | Initiates: Outperform | $58 | $25.60 | +126.56% | 1 | Apr 13, 2017 |
AbbVie
Feb 4, 2021
Maintains: Outperform
Price Target: $129 → $135
Current: $181.68
Upside: -25.69%
Perrigo Company
Jan 6, 2021
Downgrades: Sector Perform
Price Target: $59 → $49
Current: $26.29
Upside: +86.38%
Pfizer
Dec 16, 2020
Downgrades: Sector Perform
Price Target: $43 → $42
Current: $22.60
Upside: +85.84%
Jazz Pharmaceuticals
Nov 3, 2020
Maintains: Outperform
Price Target: $170 → $180
Current: $106.07
Upside: +69.70%
Merck & Co.
Apr 1, 2020
Maintains: Sector Perform
Price Target: $92 → $89
Current: $74.80
Upside: +18.98%
Amneal Pharmaceuticals
Jan 2, 2020
Maintains: Sector Perform
Price Target: $3 → $4
Current: $7.50
Upside: -46.67%
OptiNose
Nov 7, 2017
Initiates: Outperform
Price Target: $495
Current: $9.56
Upside: +5,077.82%
Teva Pharmaceutical Industries
Aug 4, 2017
Downgrades: Underperform
Price Target: n/a
Current: $16.87
Upside: -
Pacira BioSciences
Apr 13, 2017
Initiates: Outperform
Price Target: $58
Current: $25.60
Upside: +126.56%